GlassScriptPhysician profile
Katherine Hernandez
NPI 1316683824
$8,448.71
in general payments reported to CMS, 2019-2025
23 companies · $4,383 in 2025
The $4,383 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $76.91 · 2023: $856 · 2024: $3,132 · 2025: $4,383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,797 · Education: $575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,797.12 |
| Education | $574.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,464.58 | 2023-2025 | Tremfya |
| Incyte Corporation | $1,103.64 | 2023-2025 | Opzelura, Opzelura |
| Pfizer INC. | $919.01 | 2022-2025 | |
| Abbvie INC. | $724.69 | 2024-2025 | |
| Genzyme Corporation | $546.97 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $515.32 | 2022-2025 | Absorica Ld, Winlevi |
| Regeneron Healthcare Solutions, INC. | $425.70 | 2023-2025 | Dupixent |
| Galderma Laboratories, L.P. | $410.68 | 2024-2025 | Nemluvio, Aklief |
| Ucb, INC. | $343.72 | 2024-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $282.05 | 2024-2025 | |
| Leo Pharma INC. | $280.38 | 2024-2025 | Adbry, Anzupgo, Spevigo |
| Arcutis Biotherapeutics, INC. | $238.64 | 2024-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $233.23 | 2024-2025 | Spevigo |
| Lilly USA, LLC | $206.14 | 2024-2025 | Ebglyss, Taltz |
| Organon LLC | $178.93 | 2025 | Vtama, Nexplanon |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $173.00 | 2024-2025 | Cabtreo, Jublia, Arazlo |
| Alexion Pharmaceuticals, INC. | $113.65 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $108.56 | 2024-2025 | Sotyktu |
| Gilead Sciences, INC. | $84.40 | 2024-2025 | |
| Dermavant Sciences, INC. | $27.29 | 2024 | Vtama |
| Mayne Pharma Commercial LLC | $26.71 | 2025 | |
| Lnhc, INC | $21.88 | 2025 | Zelsuvmi |
| Botanix Sb INC | $19.54 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.